Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins. Mavacamten, a first-in-class allosteric inhibitor of cardiac-specific myosin, has demonstrated efficacy and safety in international clinical tria...

Full description

Bibliographic Details
Main Authors: Qing Zhang, Fang Wang, Yaling Han, Jing Sun, Shuyang Zhang, Wei Jin, Zhuang Tian, Ping Yang, Geng Wang, Jingmin Zhou, Peiwen Hsu
Format: Article
Language:English
Published: BMJ Publishing Group 2023-06-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/6/e071473.full

Internet

https://bmjopen.bmj.com/content/13/6/e071473.full

Similar Items